Rate of exposure to Mayaro virus (MAYV) in Brazil between 1955 and 2018: a systematic review and meta-analysis

Lima, William Gustavo; Pereira, Rafaela Vaz Sousa; Nizer, Waleska Stephanie da Cruz; Brito, Júlio César Moreira; Godói, Isabella Piassi Dias; Cardoso, Valbert Nascimento; Fernandes, Simone Odília Antunes; Ferreira, Jaqueline Maria Siqueira

doi:10.1007/s00705-020-04889-9

Cited by 19 publications

(18 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MAYV was isolated for the first time from the sera of forest workers in Trinidad and Tobago in 1954 [ 3 ]. Since then, several studies have revealed increasing activity of this virus in different Latin American countries, including Brazil, Peru, French Guiana, Ecuador, Bolivia, Colombia, Venezuela, Haiti, Panama, and Trinidad and Tobago [ 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Inhibition of p38 Mitogen-Activated Protein Kinase Impairs Mayaro Virus Replication in Human Dermal Fibroblasts and HeLa Cells

Sugasti-Salazar

Llamas-González

Campos

et al. 2021

Viruses

View full text Add to dashboard Cite

Mayaro virus (MAYV) hijacks the host’s cell machinery to effectively replicate. The mitogen-activated protein kinases (MAPKs) p38, JNK, and ERK1/2 have emerged as crucial cellular factors implicated in different stages of the viral cycle. However, whether MAYV uses these MAPKs to competently replicate has not yet been determined. The aim of this study was to evaluate the impact of MAPK inhibition on MAYV replication using primary human dermal fibroblasts (HDFs) and HeLa cells. Viral yields in supernatants from MAYV-infected cells treated or untreated with inhibitors SB203580, SP600125, U0126, or Losmapimod were quantified using plaque assay. Additionally, viral protein expression was analyzed using immunoblot and immunofluorescence. Knockdown of p38⍺/p38β isoforms was performed in HDFs using the PROTACs molecule NR-7h. Our data demonstrated that HDFs are highly susceptible to MAYV infection. SB203580, a p38 inhibitor, reduced MAYV replication in a dose-dependent manner in both HDFs and HeLa cells. Additionally, SB203580 significantly decreased viral E1 protein expression. Similarly, knockdown or inhibition of p38⍺/p38β isoforms with NR-7h or Losmapimod, respectively, affected MAYV replication in a dose-dependent manner. Collectively, these findings suggest that p38 could play an important role in MAYV replication and could serve as a therapeutic target to control MAYV infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Inhibition of p38 Mitogen-Activated Protein Kinase Impairs Mayaro Virus Replication in Human Dermal Fibroblasts and HeLa Cells

Sugasti-Salazar

Llamas-González

Campos

et al. 2021

Viruses

View full text Add to dashboard Cite

show abstract

“…These arthropod species are distributed nationwide, and the fact that most of the population has never been in contact with MAYV considerably increases the potential of viral emergence and the threat of large epidemics. Moreover, it is known that Aedes albopictus is resistant to lower temperatures, which can facilitate its spread to temperate regions where the virus is non-endemic [12]. As confirmed by an epidemiological study, Brazil has the highest number of MAYV reported cases (1304).…”

Section: Introductionmentioning

confidence: 92%

Evaluation of Antiviral Activity of Cyclic Ketones against Mayaro Virus

Fernandes

Silva

Dias

et al. 2021

Viruses

View full text Add to dashboard Cite

Mayaro virus (MAYV) is a neglected arthropod-borne virus found in the Americas. MAYV infection results in Mayaro fever, a non-lethal debilitating disease characterized by a strong inflammatory response affecting the joints and muscles. MAYV was once considered endemic to forested areas in Brazil but has managed to adapt and spread to urban regions using new vectors, such as Aedes aegypti, and has the potential to cause serious epidemics in the future. Currently, there are no vaccines or specific treatments against MAYV. In this study, the antiviral activity of a series of synthetic cyclic ketones were evaluated for the first time against MAYV. Twenty-four compounds were screened in a cell viability assay, and eight were selected for further evaluation. Effective concentration (EC50) and selectivity index (SI) were calculated and compound 9-(5-(4-chlorophenyl]furan-2-yl)-3,6-dimethyl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2))-dione (9) (EC50 = 21.5 µmol·L–1, SI = 15.8) was selected for mechanism of action assays. The substance was able to reduce viral activity by approximately 70% in both pre-treatment and post-treatment assays.

show abstract

“…First isolated in Mayaro, Trinidad and Tobago in 1954 1 , 2 , its current geographical distribution exclusively encompasses Central and South American countries, mainly those containing extensive areas of tropical forests 3 – 9 . MAYV was first isolated in Brazil in 1955, and since then, it has been the cause of several epidemics in the North and Central-West regions, where it can be considered endemic 10 – 13 . The most recent incidence was in a cluster of individuals from a rural village of Venezuela infected in 2010 14 .…”

Section: Introductionmentioning

confidence: 99%

Performance assessment of a multi-epitope chimeric antigen for the serological diagnosis of acute Mayaro fever

Napoleão-Pêgo

Carneiro

Durans

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Mayaro virus (MAYV), which causes mayaro fever, is endemic to limited regions of South America that may expand due to the possible involvement of Aedes spp. mosquitoes in its transmission. Its effective control will require the accurate identification of infected individuals, which has been restricted to nucleic acid-based tests due to similarities with other emerging members of the Alphavirus genus of the Togaviridae family; both in structure and clinical symptoms. Serological tests have a more significant potential to expand testing at a reasonable cost, and their performance primarily reflects that of the antigen utilized to capture pathogen-specific antibodies. Here, we describe the assembly of a synthetic gene encoding multiple copies of antigenic determinants mapped from the nsP1, nsP2, E1, and E2 proteins of MAYV that readily expressed as a stable chimeric protein in bacteria. Its serological performance as the target in ELISAs revealed a high accuracy for detecting anti-MAYV IgM antibodies. No cross-reactivity was observed with serum from seropositive individuals for dengue, chikungunya, yellow fever, Zika, and other infectious diseases as well as healthy individuals. Our data suggest that this bioengineered antigen could be used to develop high-performance serological tests for MAYV infections.

show abstract

Rate of exposure to Mayaro virus (MAYV) in Brazil between 1955 and 2018: a systematic review and meta-analysis

Cited by 19 publications

References 31 publications

Inhibition of p38 Mitogen-Activated Protein Kinase Impairs Mayaro Virus Replication in Human Dermal Fibroblasts and HeLa Cells

Inhibition of p38 Mitogen-Activated Protein Kinase Impairs Mayaro Virus Replication in Human Dermal Fibroblasts and HeLa Cells

Evaluation of Antiviral Activity of Cyclic Ketones against Mayaro Virus

Performance assessment of a multi-epitope chimeric antigen for the serological diagnosis of acute Mayaro fever

Contact Info

Product

Resources

About